Millions Received River Blindness Treatment in 2025
The World Health Organization reported that over 180 million people received preventative care for the parasitic disease.
Updated on Oct. 12, 2026 in Diseases — General
Live Poll
Do you trust international health organizations to maintain consistent disease prevention services for underserved global populations?
In 2025, the World Health Organization recorded 180.3 million people receiving treatment for onchocerciasis, commonly known as river blindness. Despite this, significant gaps in care persisted for more than 75 million people who required treatment but did not receive it.
Why it matters
Universal access remains elusive due to funding delays, administrative challenges, and co-infection safety concerns that disrupt mass drug administration programs. Addressing these gaps is essential to move more regions toward elimination and post-treatment surveillance.
A WHO report documented 180.3 million people receiving mass drug administration for onchocerciasis in 2025, achieving a global coverage rate of 70.5%. While 38 million people reached the milestone of post-treatment surveillance, 75.4 million individuals requiring care were not reached.
The players
World Health Organization
The international public health agency responsible for coordinating global efforts to control and eliminate infectious diseases.
The details
The program primarily utilizes mass drug administration of ivermectin to interrupt the transmission cycle of the parasite Onchocerca volvulus. Elimination strategies focus on treating entire populations in endemic areas to reduce the parasitic load until it is low enough to transition to surveillance. However, efforts are hindered by funding instability in countries like Cameroon and safety protocols in Gabon that limit administration due to the risk of Loa loa co-infection.
Timeline
In 2025, 180.3 million people were treated for river blindness.
The World Health Organization published the progress report on October 9, 2026.
Health Landscape
The current global approach relies on transitioning from mass drug administration to post-treatment surveillance as endemic areas meet specific thresholds. This update illustrates how regional socioeconomic factors and biological complexities continue to challenge the broader elimination timeline.
While these mass programs are targeted at specific endemic regions, understanding the reach of preventative care helps monitor the global fight against parasitic infections. Residents in affected areas should consult with local health authorities regarding the availability and scheduling of regional drug administration.
The takeaway
Ongoing funding and administrative stability are the primary obstacles to achieving full coverage for river blindness. Tracking the progress of elimination programs in endemic regions remains a vital metric for assessing the impact of global parasitic disease initiatives.
Further reading
Learn more about global initiatives in our Diseases — General section.
Source note: This article includes information reported by PakTribune.
Live Poll
Do you trust international health organizations to maintain consistent disease prevention services for underserved global populations?
